Tardive dyskinesia: Clinical presentation and treatment

International Review of Neurobiology

Volumn 98, Issue , 2011, Pages 187-210

  van Harten, Peter N ^a   Tenback, Diederik E ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Clinical features; Diagnosis; Differential diagnosis; Genetics; Pathophysiology; Prevention; Tardive dyskinesia; Treatment

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; PLACEBO; TETRABENAZINE;

AKATHISIA; BINDING AFFINITY; BOOK; CLINICAL FEATURE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; FOCAL DYSTONIA; HUMAN; HYPERKINESIA; INTERPERSONAL COMMUNICATION; LIMB TRUNCAL DYSKINESIA; MASS SCREENING; MOTOR DYSFUNCTION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; OROFACIAL DYSKINESIA; PARKINSONISM; PRIORITY JOURNAL; PROTEIN FUNCTION; RESPIRATORY DYSKINESIA; RISK FACTOR; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

EID: 80052524421     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381328-2.00008-0     Document Type: Chapter

References (115)

1. Adler L.A., Rotrosen J., Edson R., Lavori P., Lohr J., Hitzemann R., Raisch D., Caligiuri M., Tracy K. Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch. Gen. Psychiatry 1999, 56:836-841.
2. Alentorn A., Palasi A., Campdelacreu J., Bruna J., Calopa M., Rubio F. Pelvic dyskinesia with an outstanding response to tetrabenazine. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:847-848.
3. APA (1992). Tardive dyskinesia: a task force report of the American Psychiatric Association. The American Psychiatric Association: Washington.
4. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision.
5. Barbui C., Nose M., Mazzi M.A., Thornicroft G., Schene A., Becker T., Bindman J., Leese M., Helm H., Koeter M., Weinmann S., Tansella M. Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. Int. Clin. Psychopharmacol. 2006, 21:355-362.
6. Bhoopathi P.S., Soares-Weiser K. Benzodiazepines for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst. Rev. 2006, 3. CD000205.
7. Bouchard M., Chouinard S., Suchowersky O. Adult cases of congenital muscular torticollis successfully treated with botulinum toxin. Mov. Disord. 2010, 25:2453-2456.
8. Boumans C.E., de Mooij K.J., Koch P.A., van't Hof M.A., Zitman F.G. Is the social acceptability of psychiatric patients decreased by orofacial dyskinesia?. Schizophr. Bull. 1994, 20:339-344.
9. Broekema W.J., de Groot I.W., van Harten P.N. Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics-a European study. Pharm. World Sci. 2007, 29:126-130.
10. Bronstein J.M., Tagliati M., Alterman R.L., Lozano A.M., Volkmann J., Stefani A., Horak F.B., Okun M.S., Foote K.D., Krack P., Pahwa R., Henderson J.M., Hariz M.I., Bakay R.A., Rezai A., Marks W.J., Moro E., Vitek J.L., Weaver F.M., Gross R.E., Delong M.R. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol. 2011, 68:165.
11. Bruscas M.J., Gonzalez F., Santos J.L., Sanchez E. Tardive dyskinesia associated with clozapine treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:963-964.
12. Casey D.E. Tardive dyskinesia. West J. Med. 1990, 153:535-541.
13. Casey D.E. Pathophysiology of antipsychotic drug-induced movement disorders. J. Clin. Psychiatry 2004, 65(Suppl 9):25-28.
14. Casey D.E. Implications of the CATIE trial on treatment: extrapyramidal symptoms. CNS Spectr. 2006, 11:25-31.
15. Chan H.Y., Chiang S.C., Chang C.J., Gau S.S., Chen J.J., Chen C.H., Hwu H.G., Lai M.S. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia. J. Clin. Psychiatry 2010, 71:1226-1233.
16. Chaplin R., Kent A. Informing patients about tardive dyskinesia. Controlled trial of patient education. Br. J. Psychiatry 1998, 172:78-81.
17. Chaplin R., Timehin C. Informing patients about tardive dyskinesia: four-year follow up of a trial of patient education. Aust. N. Z. J. Psychiatry 2002, 36:99-103.
18. Charles P.D., Davis T.L., Shannon K.M., Hook M.A., Warner J.S. Tongue protrusion dystonia: treatment with botulinum toxin. South Med. J. 1997, 90:522-525.
19. Chong S.A., Remington G., Mahendran R., Chua H.C. Awareness of tardive dyskinesia in Asian patients with schizophrenia. J. Clin. Psychopharmacol. 2001, 21:235-237.
20. Citrome L., Reist C., Palmer L., Montejano L., Lenhart G., Cuffel B., Harnett J., Sanders K.N. Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder. Schizophr. Res. 2009, 108:238-244.
21. Cohen O.S., Hassin-Baer S., Spiegelmann R. Deep brain stimulation of the internal globus pallidus for refractory tardive dystonia. Parkinsonism Relat. Disord. 2007, 13:541-544.
22. Correll C.U., Schenk E.M. Tardive dyskinesia and new antipsychotics. Curr. Opin. Psychiatry 2008, 21:151-156.
23. Crow T.J., Owens D.G., Johnstone E.C., Cross A.J., Owen F. Does tardive dyskinesia exist?. Mod. Probl. Pharmacopsychiatry 1983, 21:206-219.
24. Dalack G.W., Becks L., Meador-Woodruff J.H. Tardive dyskinesia, clozapine, and treatment response. Prog. Neuropsychopharmacol. Biol. Psychiatry 1998, 22:567-573.
25. Damier P., Thobois S., Witjas T., Cuny E., Derost P., Raoul S., Mertens P., Peragut J.C., Lemaire J.J., Burbaud P., Nguyen J.M., Llorca P.M., Rascol O. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch. Gen. Psychiatry 2007, 64:170-176.
26. de Haan L., Lavalaye J., van Bruggen M., van Nimwegen L., Booij J., van Amelsvoort T., Linszen D. Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications. Can. J. Psychiatry 2004, 49:290-296.
27. De Haan L., Van Bruggen M., Lavalaye J., Booij J., Dingemans P.M., Linszen D. Subjective experience and d(2) receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am. J. Psychiatry 2003, 160:303-309.
28. Duggal H.S., Mendhekar D.N. Clozapine-induced tardive dystonia (blepharospasm). J. Neuropsychiatry Clin. Neurosci. 2007, 19:86-87.
29. Ellison D.C., Wandres D.L. Botulinum A toxin in spasmodic torticollis. Ann. Pharmacother. 1992, 26:216-217.
30. Eltahawy H.A., Feinstein A., Khan F., Saint-Cyr J., Lang A.E., Lozano A.M. Bilateral globus pallidus internus deep brain stimulation in tardive dyskinesia: a case report. Mov. Disord. 2004, 19:969-972.
31. Emsley R., Niehaus D.J., Oosthuizen P.P., Koen L., Chiliza B., Fincham D. Subjective awareness of tardive dyskinesia and insight in schizophrenia. Eur Psychiatry. 2011, 26:293-296.
32. Emsley R., Turner H.J., Schronen J., Botha K., Smit R., Oosthuizen P.P. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J. Clin. Psychiatry 2004, 65:696-701.
33. Ertugrul A., Demir B. Clozapine-induced tardive dyskinesia: a case report. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:633-635.
34. Espay A.J., Goldenhar L.M., Voon V., Schrag A., Burton N., Lang A.E. Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: an international survey of movement disorder society members. Mov. Disord. 2009, 24:1366-1374.
35. Fenton W.S. Prevalence of spontaneous dyskinesia in schizophrenia. J. Clin. Psychiatry 2000, 61(Suppl 4):10-14.
36. Fernandez H.H., Friedman J.H. Classification and treatment of tardive syndromes. Neurologist 2003, 9:16-27.
37. Freed E. Tardive dyskinesia-subjective discomfort from psychosocial stress. S. Afr. Med. J. 1982, 62:80.
38. Gaebel W. Intermittent medication-an alternative?. Acta Psychiatr. Scand. 1994, 89:33-38.
39. Ganguly R., Kotzan J.A., Miller L.S., Kennedy K., Martin B.C. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J. Clin. Psychiatry 2004, 65:1377-1388.
40. Gill H.S., Kraft S.P. Long-term efficacy of botulinum a toxin for blepharospasm and hemifacial spasm. Can. J. Neurol. Sci. 2010, 37:631-636.
41. Goldman M.B., Luchins D.J. Intermittent neuroleptic therapy and tardive dyskinesia: a literature review. Hosp. Community Psychiatry 1984, 35:1215-1219.
42. Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology. U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs: Rockville, MD.
43. Hennings J.M., Krause E., Botzel K., Wetter T.C. Successful treatment of tardive lingual dystonia with botulinum toxin: case report and review of the literature. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1167-1171.
44. Heres S., Davis J., Maino K., Jetzinger E., Kissling W., Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am. J. Psychiatry 2006, 163:185-194.
45. Hyde T.M., Apud J.A., Fisher W.C., Egan M.F. Tardive dyskinesia. Drug Induced Movement Disorders 2005, 213-256. Blackwell Publishing, Massachusetts. S.A. Factor, A.E. Lang, W.J. Weiner (Eds.).
46. Jankovic J., Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 1988, 38:391-394.
47. Janno S., Holi M., Tuisku K., Wahlbeck K. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am. J. Psychiatry 2004, 161:160-163.
48. Jeste D.V. Tardive dyskinesia in older patients. J. Clin. Psychiatry 2000, 61(Suppl 4):27-32.
49. Jeste D.V. Tardive dyskinesia rates with atypical antipsychotics in older adults. J. Clin. Psychiatry 2004, 65(Suppl 9):21-24.
50. Jeste D.V., Lohr J.B., Clark K., Wyatt R.J. Pharmacological treatments of tardive dyskinesia in the 1980 s. J. Clin. Psychopharmacol. 1988, 8:38S-48S.
51. Jeste D.V., Wyatt R.J. Therapeutic strategies against tardive dyskinesia. Two decades of experience. Arch. Gen. Psychiatry 1982, 39:803-816.
52. Jones P.B., Barnes T.R., Davies L., Dunn G., Lloyd H., Hayhurst K.P., Murray R.M., Markwick A., Lewis S.W. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry 2006, 63:1079-1087.
53. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., Gheorghe M.D., Rybakowski J.K., Galderisi S., Libiger J., Hummer M., Dollfus S., Lopez-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rossler A., Grobbee D.E. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371:1085-1097.
54. Kane J.M., Marder S.R. Psychopharmacologic treatment of schizophrenia. Schizophr. Bull. 1993, 19:287-302.
55. Kane J.M., Woerner M., Borenstein M., Wegner J., Lieberman J. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol. Bull. 1986, 22:254-258.
56. Kapur S., Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am. J. Psychiatry 2001, 158:360-369.
57. Kefalopoulou Z., Paschali A., Markaki E., Vassilakos P., Ellul J., Constantoyannis C. A double-blind study on a patient with tardive dyskinesia treated with pallidal deep brain stimulation. Acta Neurol. Scand. 2009, 119:269-273.
58. Kenney C., Hunter C., Mejia N., Jankovic J. Is history of depression a contraindication to treatment with tetrabenazine?. Clin. Neuropharmacol. 2006, 29:259-264.
59. Kenney C., Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev. Neurother. 2006, 6:7-17.
60. Koller W.C., Lyons K.E., Wilkinson S.B., Troster A.I., Pahwa R. Long-term safety and efficacy of unilateral deep brain stimulation of the thalamus in essential tremor. Mov. Disord. 2001, 16:464-468.
61. Koning J.P., Tenback D.E., van Os J., Aleman A., Kahn R.S., van Harten P.N. Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis. Schizophr. Bull. 2010, 36:723-731.
62. Kruk J., Sachdev P., Singh S. Neuroleptic-induced respiratory dyskinesia. J. Neuropsychiatry Clin. Neurosci. 1995, 7:223-229.
63. Lerner V., Miodownik C., Kaptsan A., Bersudsky Y., Libov I., Sela B.A., Witztum E. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. J. Clin. Psychiatry 2007, 68:1648-1654.
64. Lerner V., Miodownik C., Kaptsan A., Cohen H., Matar M., Loewenthal U., Kotler M. Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Am. J. Psychiatry 2001, 158:1511-1514.
65. Li C.R., Chung Y.C., Park T.W., Yang J.C., Kim K.W., Lee K.H., Hwang I.K. Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug. World J. Biol. Psychiatry 2009, 10:919-924.
66. Lieberman J.A. An interview with Jeffrey A. Lieberman: tardive dyskinesia. [interview by Sussman Norman]. CNS Spectr. 2007, 12:747-750.
67. Lieberman J.A., Saltz B.L., Johns C.A., Pollack S., Borenstein M., Kane J. The effects of clozapine on tardive dyskinesia. Br. J. Psychiatry 1991, 158:503-510.
68. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353:1209-1223.
69. Louza M.R., Bassitt D.P. Maintenance treatment of severe tardive dyskinesia with clozapine: 5 years' follow-up. J. Clin. Psychopharmacol. 2005, 25:180-182.
70. Macpherson R., Collis R. Tardive dyskinesia. Patients' lack of awareness of movement disorder. Br. J. Psychiatry 1992, 160:110-112.
71. Margolese H.C., Chouinard G., Kolivakis T.T., Beauclair L., Miller R. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can. J. Psychiatry 2005, 50:541-547.
72. McCreadie R.G., Padmavati R., Thara R., Srinivasan T.N. Spontaneous dyskinesia and parkinsonism in never-medicated, chronically ill patients with schizophrenia: 18-month follow-up. Br. J. Psychiatry 2002, 181:135-137.
73. Mejia N.I., Jankovic J. Tardive dyskinesia and withdrawal emergent syndrome in children. Expert Rev. Neurother. 2010, 10:893-901.
74. Miyasaki J.M., Sa D.S., Galvez-Jimenez N., Lang A.E. Psychogenic movement disorders. Can. J. Neurol. Sci. 2003, 30(Suppl 1):S94-100.
75. Mizrahi R., Rusjan P., Agid O., Graff A., Mamo D.C., Zipursky R.B., Kapur S. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. Am. J. Psychiatry 2007, 164:630-637.
76. Nakamura J., Otsuka M., Kuniyoshi M., Inanaga K. Three cases of respiratory dyskinesia. Jpn. J. Psychiatry Neurol. 1991, 45:833-841.
77. Nelson L.A., McGuire J.M., Hausafus S.N. Melatonin for the treatment of tardive dyskinesia. Ann. Pharmacother. 2003, 37:1128-1131.
78. Ondo W.G., Hanna P.A., Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am. J. Psychiatry 1999, 156:1279-1281.
79. Paulsen J.S., Caligiuri M.P., Palmer B., McAdams L.A., Jeste D.V. Risk factors for orofacial and limbtruncal tardive dyskinesia in older patients: a prospective longitudinal study. Psychopharmacology (Berl) 1996, 123:307-314.
80. Raguraman J., Vijaysagar J. Worsening of tardive dyskinesia due to clozapine therapy. J. Postgrad. Med. 2007, 53:218.
81. Rao A.S., Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment. Pharmacol. Ther. 2010, 31:11-19.
82. Rapaport A., Sadeh M., Stein D., Levine J., Sirota P., Mosheva T., Stir S., Elitzur A., Reznik I., Geva D., Rabey J.M. Botulinum toxin for the treatment of oro-facial-lingual-masticatory tardive dyskinesia. Mov. Disord. 2000, 15:352-355.
83. Rathbone J., Soares-Weiser K. Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst. Rev. 2006, CD003727.
84. Remington G., Kapur S. Antipsychotic dosing: how much but also how often?. Schizophr. Bull. 2010, 36:900-903.
85. Schilsky M.L. Wilson disease: current status and the future. Biochimie 2009, 91:1278-1281.
86. Schooler N.R., Kane J.M. Research diagnoses for tardive dyskinesia. Arch. Gen. Psychiatry 1982, 39:486-487.
87. Schrader C., Peschel T., Petermeyer M., Dengler R., Hellwig D. Unilateral deep brain stimulation of the internal globus pallidus alleviates tardive dyskinesia. Mov. Disord. 2004, 19:583-585.
88. Shamir E., Barak Y., Shalman I., Laudon M., Zisapel N., Tarrasch R., Elizur A., Weizman R. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch. Gen. Psychiatry 2001, 58:1049-1052.
89. Shprecher D., Kurlan R. The management of tics. Mov. Disord. 2009, 24:15-24.
90. Silvestri S., Seeman M.V., Negrete J.C., Houle S., Shammi C.M., Remington G.J., Kapur S., Zipursky R.B., Wilson A.A., Christensen B.K., Seeman P. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 2000, 152:174-180.
91. Skidmore F., Weiner W.J., Burke R. Neuroleptic-induced tardive dyskinesia variants. Drug Induced Movement Disorders 2005, 257-285. Blackwell Publishing, Massachusetts. S.A. Factor, A.E. Lang, W.J. Weiner (Eds.).
92. Slotema C.W., van Harten P.N., Bruggeman R., Hoek H.W. Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:507-509.
93. Soares K.V., McGrath J.J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst. Rev. 2001, CD000209.
94. Soares-Weiser K., Fernandez H.H. Tardive dyskinesia. Semin. Neurol. 2007, 27:159-169.
95. Soares-Weiser K., Rathbone J. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database Syst. Rev. 2006, CD000459.
96. Tammenmaa I.A., Sailas E., McGrath J.J., Soares-Weiser K., Wahlbeck K. Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28:1099-1107.
97. Tamminga C.A., Thaker G.K., Moran M., Kakigi T., Gao X.M. Clozapine in tardive dyskinesia: observations from human and animal model studies. J. Clin. Psychiatry 1994, 55(Suppl B):102-106.
98. Tarbox S.I., Pogue-Geile M.F. Spontaneous dyskinesia and familial liability to schizophrenia. Schizophr. Res. 2006, 81:125-137.
99. Tauscher J., Hussain T., Agid O., Verhoeff N.P., Wilson A.A., Houle S., Remington G., Zipursky R.B., Kapur S. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am. J. Psychiatry 2004, 161:1620-1625.
100. Tenback D.E., van Harten P.N., Slooff C.J., van Os J. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Am. J. Psychiatry 2006, 163:1438-1440.
101. Tenback D.E., van Harten P.N., Slooff C.J., van Os J. Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia. J. Psychopharmacol. 2010, 24:1031-1035.
102. Tenback D.E., van Harten P.N., van Os J. Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis. Mov. Disord. 2009, 24:2309-2315.
103. Trottenberg T., Volkmann J., Deuschl G., Kuhn A.A., Schneider G.H., Muller J., Alesch F., Kupsch A. Treatment of severe tardive dystonia with pallidal deep brain stimulation. Neurology 2005, 64:344-346.
104. Tschopp L., Salazar Z., Micheli F. Botulinum toxin in painful tardive dyskinesia. Clin. Neuropharmacol. 2009, 32:165-166.
105. Turrone P., Remington G., Kapur S., Nobrega J.N. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. Psychopharmacology (Berl) 2003, 165:166-171.
106. Turrone P., Remington G., Kapur S., Nobrega J.N. Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats. Biol. Psychiatry 2005, 57:406-411.
107. van Harten P.N. Movement Disorders Associated With Neuroleptics: The Curacao Extrapyramidal Syndromes Study 1998, University of Utrecht, Utrecht. http://igitur-archive.library.uu.nl/dissertations/2007-0119-200638/UUindex.html.
108. van Harten P.N., Hoek H.W., Kahn R.S. Acute dystonia induced by drug treatment. BMJ 1999, 319:623-626.
109. van Harten P.N., Hoek H.W., Matroos G.E., Koeter M., Kahn R.S. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curacao Extrapyramidal Syndromes Study III. Am. J. Psychiatry 1998, 155:565-567.
110. van Harten P.N., Hovestadt A. Botulinum toxin as a treatment for tardive dyskinesia. Mov. Disord. 2006, 21:1276-1277.
111. van Harten P.N., Kamphuis D.J., Matroos G.E. Use of clozapine in tardive dystonia. Prog. Neuropsychopharmacol. Biol. Psychiatry 1996, 20:263-274.
112. van Harten P.N., Matroos G.E., Hoek H.W., Kahn R.S. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The Curacao Extrapyramidal Syndromes Study: I. Schizophr. Res. 1996, 19:195-203.
113. Wiggelinkhuizen M., Tilanus M.E., Bollen C.W., Houwen R.H. Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease. Aliment. Pharmacol. Ther. 2009, 29:947-958.
114. Yassa R., Lal S. Respiratory irregularity and tardive dyskinesia. A prevalence study. Acta Psychiatr. Scand. 1986, 73:506-510.
115. Zhang J.G., Zhang K., Wang Z.C. Deep brain stimulation in the treatment of tardive dystonia. Chin. Med. J. (Engl) 2006, 119:789-792.